- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Incanthera PLC - Commercial Update | - | RNS | ||
| 11.12.25 | Incanthera launches Skin+Cell skincare line via direct-to-consumer | 6 | Investing.com | ||
| 11.12.25 | Incanthera startet Hautpflegelinie Skin+Cell im Direktvertrieb | 2 | Investing.com Deutsch | ||
| 11.12.25 | Incanthera PLC - Half-year Report | - | RNS | ||
| INCANTHERA Aktie jetzt für 0€ handeln | |||||
| 30.06.25 | Aquis Stock Exchange: Notification of APEX constituent review - Incanthera Plc | 443 | EQS Group (EN) | Aquis Stock Exchange
Aquis Stock Exchange: Notification of APEX constituent review 30-Jun-2025 / 07:00 GMT/BST
The issuer is solely responsible for the... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AKARI THERAPEUTICS | 18,230 | -0,22 % | Akari Therapeutics Plc: Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models | An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer modelsData... ► Artikel lesen | |
| BAYER | 38,520 | -1,00 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
19.05.2026... ► Artikel lesen | |
| MERCK KGAA | 128,55 | +1,70 % | BARCLAYS stuft MERCK KGAA auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Merck KGaA mit einem Kursziel von 130 Euro auf "Equal Weight" belassen. Das erste Quartal des Pharma- und Chemiekonzerns... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 32,560 | -0,09 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 14,540 | +0,07 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| FUNCTIONAL BRANDS | 0,106 | -0,09 % | Functional Brands Inc.: Functional Brands Enters into Agreement to Acquire Alchemy, a Gold-Backed Blockchain Settlement Platform, in a $142.9 Million Transaction | Lake Oswego, Oregon--(Newsfile Corp. - May 22, 2026) - Functional Brands Inc. (NASDAQ: MEHA) ("Functional Brands" or the "Company") today announced the execution of a definitive agreement for the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,120 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 83,70 | +0,24 % | Bright Minds Biosciences GAAP EPS of -$1.09 for three months ended March 31 | ||
| NOVO NORDISK | 38,875 | +2,20 % | BARCLAYS stuft NOVO NORDISK auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Novo Nordisk mit einem Kursziel von 300 dänischen Kronen auf "Equal Weight" belassen. Nach starkem Start hätten... ► Artikel lesen | |
| LB PHARMACEUTICALS | 28,160 | +0,14 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,080 | -0,08 % | Atrium Therapeutics Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,410 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update | CARDAMYST (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,715 | +0,40 % | Kazia Therapeutics Limited: Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform | SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with... ► Artikel lesen | |
| OMNIAB | 2,640 | -0,38 % | OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook | ||
| SUNSHINE BIOPHARMA | 0,481 | 0,00 % | Sunshine Biopharma Inc.: Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin | FORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications... ► Artikel lesen |
Das Unternehmen INCANTHERA PLC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INCANTHERA PLC finden Sie auf Wallstreet Online.